Membranous glomerulonephritis

Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly people between ages of 30 and 50 years, usually Caucasian.

Membranous glomerulonephritis
Micrograph of membranous nephropathy showing prominent glomerular basement membrane spikes. Jones' stain.
SpecialtyNephrology 

It is the second most common cause of nephrotic syndrome in adults, with focal segmental glomerulosclerosis (FSGS) recently becoming the most common.[1]

Signs and symptoms

Most people will present as nephrotic syndrome, with the triad of albuminuria, edema and low serum albumin (with or without kidney failure). High blood pressure and high cholesterol are often also present. Others may not have symptoms and may be picked up on screening, with urinalysis finding high amounts of protein loss in the urine. A definitive diagnosis of membranous nephropathy requires a kidney biopsy, though given the very high specificity of anti-PLA2R antibody positivity this can sometimes be avoided in patients with nephrotic syndrome and preserved kidney function[2]

Causes

Primary/idiopathic

85% of MGN cases are classified as primary membranous glomerulonephritis—that is to say, the cause of the disease is idiopathic (of unknown origin or cause). This can also be referred to as idiopathic membranous nephropathy.


One study has identified antibodies to an M-type phospholipase A2 receptor in 70% (26 of 37) cases evaluated.[3] Testing for these anti-PLA2R has revolutionised diagnosis and treatment of this disease in antibody positive patients, and tracking titre level over time allows you to predict risk of disease progression and chance of spontaneous remission[4]


In 2014, a second autoantigen was discovered, the thrombospondin type 1 domain-containing 7A (THSD7A) system that might account for an additional 5-10% of membranous nephropathy cases, and appears to be associated with malignancies.[5] New studies are identifying novel auto-antigens responsible for membranous nephropathy continue to be published, with antibodies against NELL-1[6] and EXT1/EXT2[7] in 2019.

Secondary

The remainder is secondary due to:

Pathogenesis
Immune complexes (black) are deposited in a thickened basement membrane creating a "spike and dome" appearance on electron microscopy.

MGN is caused by immune complex formation in the glomerulus. The immune complexes are formed by binding of antibodies to antigens in the glomerular basement membrane. The antigens may be part of the basement membrane, or deposited from elsewhere by the systemic circulation.

The immune complex serves as an activator that triggers a response from the C5b - C9 complements, which form a membrane attack complex (MAC) on the glomerular epithelial cells. This, in turn, stimulates release of proteases and oxidants by the mesangial and epithelial cells, damaging the capillary walls and causing them to become "leaky". In addition, the epithelial cells also seem to secrete an unknown mediator that reduces nephrin synthesis and distribution.

Within membranous glomerulonephritis, especially in cases caused by viral hepatitis, serum C3 levels are low.[13]

Similar to other causes of nephrotic syndrome (e.g., focal segmental glomerulosclerosis or minimal change disease), membranous nephropathy is known to predispose affected individuals to develop blood clots such as pulmonary emboli. Membranous nephropathy in particular is known to increase this risk more than other causes of nephrotic syndrome though the reason for this is not yet clear.

Morphology

The defining point of MGN is the presence of subepithelial immunoglobulin-containing deposits along the glomerular basement membrane (GBM).

  • By light microscopy, the basement membrane is observed to be diffusely thickened. Using Jones' stain, the GBM appears to have a "spiked" or "holey" appearance.
  • On electron microscopy, subepithelial deposits that nestle against the glomerular basement membrane seems to be the cause of the thickening. Also, the podocytes lose their foot processes. As the disease progresses, the deposits will eventually be cleared, leaving cavities in the basement membrane. These cavities will later be filled with basement membrane-like material, and if the disease continues even further, the glomeruli will become sclerosed and finally hyalinized.
  • Immunofluorescence microscopy will reveal typical granular deposition of immunoglobulins and complement along the basement membrane.[14]

Although it usually affects the entire glomerulus, it can affect parts of the glomerulus in some cases.[15]

Treatment

Treatment of secondary membranous nephropathy is guided by the treatment of the original disease. For treatment of idiopathic membranous nephropathy, the treatment options include immunosuppressive drugs and non-specific anti-proteinuric measures such as ACE inhibitors or angiotensin II receptor blockers. Given spontaneous remission is common, international guidelines recommend a period of watchful waiting before considering immunosuppressive treatment.[16] Likelihood of achieving spontaneous remission is much higher if anti-proteinuric therapy with ace inhibitors or angiotensin II receptor blockers is commenced.

Recommended first line immunsosuppressive therapy often includes: cyclophosphamide alternating with a corticosteroid,[17] also known as the Ponticelli regime.

Immunosuppressive therapy options
  1. Corticosteroids: They have been tried with mixed results, with one study showing prevention of progression to kidney failure without improvement in proteinuria.
  2. Chlorambucil
  3. Cyclosporine[18]
  4. Tacrolimus
  5. Cyclophosphamide
  6. Mycophenolate mofetil
  7. Rituximab

Perhaps the most difficult aspect of membranous glomerulonephritis is deciding which people to treat with immunosuppressive therapy as opposed to simple "background" or anti-proteinuric therapies. A large part of this difficulty is due to a lack of ability to predict which people will progress to end-stage kidney disease, or kidney disease severe enough to require dialysis. Because the above medications carry risk, treatment should not be initiated without careful consideration as to risk/benefit profile. Of note, corticosteroids (typically Prednisone) alone are of little benefit. They should be combined with one of the other 5 medications, each of which, along with prednisone, has shown some benefit in slowing down progression of membranous nephropathy. It must be kept in mind, however, that each of the 5 medications also carry their own risks, on top of prednisone.

The twin aims of treating membranous nephropathy are first to induce a remission of the nephrotic syndrome and second to prevent the development of end-stage kidney failure. A meta-analysis of four randomized controlled trials comparing treatments of membranous nephropathy showed that regimes comprising chlorambucil or cyclophosphamide, either alone or with steroids, were more effective than symptomatic treatment or treatment with steroids alone in inducing remission of the nephrotic syndrome.

Prognosis

About a third of untreated patients have spontaneous remission, another third progress to require dialysis and the last third continue to have proteinuria, without progression of kidney failure.

Terminology

The closely related terms membranous nephropathy (MN)[19] and membranous glomerulopathy[20] both refer to a similar constellation but without the assumption of inflammation.

Membranous nephritis (in which inflammation is implied, but the glomerulus not explicitly mentioned) is less common, but the phrase is occasionally encountered.[21] These conditions are usually considered together.

By contrast, membranoproliferative glomerulonephritis has a similar name, but is considered a separate condition with a distinctly different causality. Membranoproliferative glomerulonephritis involves the basement membrane and mesangium, while membranous glomerulonephritis involves the basement membrane but not the mesangium. (Membranoproliferative glomerulonephritis has the alternate name "mesangiocapillary glomerulonephritis", to emphasize its mesangial character.)

References
  1. Membranous Glomerulonephritis at eMedicine
  2. Bobart, Shane A.; Vriese, An S. De; Pawar, Aditya S.; Zand, Ladan; Sethi, Sanjeev; Giesen, Callen; Lieske, John C.; Fervenza, Fernando C. (2019-02-01). "Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies". Kidney International. 95 (2): 429–438. doi:10.1016/j.kint.2018.10.021. ISSN 0085-2538. PMID 30665573.
  3. Beck LH, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (July 2009). "M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy". The New England Journal of Medicine. 361 (1): 11–21. doi:10.1056/NEJMoa0810457. PMC 2762083. PMID 19571279.
  4. Logt, Anne-Els van de; Fresquet, Maryline; Wetzels, Jack F.; Brenchley, Paul (2019-12-01). "The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery". Kidney International. 96 (6): 1292–1302. doi:10.1016/j.kint.2019.07.014. ISSN 0085-2538. PMID 31611068.
  5. Tomas NM, Beck LH, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G (December 2014). "Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy". The New England Journal of Medicine. 371 (24): 2277–2287. doi:10.1056/NEJMoa1409354. PMC 4278759. PMID 25394321.
  6. Sethi, Sanjeev; Debiec, Hanna; Madden, Benjamin; Charlesworth, M. Cristine; Morelle, Johann; Gross, LouAnn; Ravindran, Aishwarya; Buob, David; Jadoul, Michel; Fervenza, Fernando C.; Ronco, Pierre (2020-01-01). "Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy". Kidney International. 97 (1): 163–174. doi:10.1016/j.kint.2019.09.014. ISSN 0085-2538. PMID 31901340.
  7. Sethi, Sanjeev; Madden, Benjamin J.; Debiec, Hanna; Charlesworth, M. Cristine; Gross, LouAnn; Ravindran, Aishwarya; Hummel, Amber M.; Specks, Ulrich; Fervenza, Fernando C.; Ronco, Pierre (2019-06-01). "Exostosin 1/Exostosin 2–Associated Membranous Nephropathy". Journal of the American Society of Nephrology. 30 (6): 1123–1136. doi:10.1681/ASN.2018080852. ISSN 1046-6673. PMC 6551791. PMID 31061139.
  8. "Renal Pathology". Retrieved 2008-11-25.
  9. "UpToDate". www.uptodate.com. Retrieved 2019-05-11.
  10. "UpToDate". www.uptodate.com. Retrieved 2019-05-11.
  11. "UpToDate". www.uptodate.com. Retrieved 2019-05-11.
  12. Ziakas PD, Giannouli S, Psimenou E, Nakopoulou L, Voulgarelis M (July 2004). "Membranous glomerulonephritis in chronic lymphocytic leukemia". American Journal of Hematology. 76 (3): 271–4. doi:10.1002/ajh.20109. PMID 15224365. S2CID 35937418.
  13. Menon S, Valentini RP (August 2010). "Membranous nephropathy in children: clinical presentation and therapeutic approach". Pediatric Nephrology. 25 (8): 1419–28. doi:10.1007/s00467-009-1324-5. PMC 2887508. PMID 19908069.
  14. "Renal Pathology". Retrieved 2008-11-25.
  15. Obana M, Nakanishi K, Sako M, Yata N, Nozu K, Tanaka R, Iijima K, Yoshikawa N (July 2006). "Segmental membranous glomerulonephritis in children: comparison with global membranous glomerulonephritis". Clinical Journal of the American Society of Nephrology. 1 (4): 723–9. doi:10.2215/CJN.01211005. PMID 17699279.
  16. "KDIGO GN guidelines" (PDF).
  17. Chen Y, Schieppati A, Chen X, Cai G, Zamora J, Giuliano GA, Braun N, Perna A (October 2014). "Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome". The Cochrane Database of Systematic Reviews (10): CD004293. doi:10.1002/14651858.CD004293.pub3. PMC 6669245. PMID 25318831.
  18. Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, Stefanidis I, Vargemezis V, Vlachojannis JG, Siamopoulos KC (2007). "Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs". American Journal of Nephrology. 27 (3): 226–31. doi:10.1159/000101367. PMID 17389782. S2CID 1475371.
  19. Passerini P, Ponticelli C (July 2003). "Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy". Seminars in Nephrology. 23 (4): 355–61. doi:10.1016/S0270-9295(03)00052-4. PMID 12923723.
  20. Markowitz GS (May 2001). "Membranous glomerulopathy: emphasis on secondary forms and disease variants". Advances in Anatomic Pathology. 8 (3): 119–25. doi:10.1097/00125480-200105000-00001. PMID 11345236. S2CID 39640332.
  21. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR (2016). "Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature". Lupus. 9 (4): 241–51. doi:10.1191/096120300680198935. PMID 10866094. S2CID 20048968.
Classification
External resources
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.